Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Quick Listen: Scrip’s Five Must-Know Things

Executive Summary

In this week's podcast edition of Five Must-Know Things: will a new oral antiviral be transformative for COVID?; OX40 drugs gain prominence in atopic dermatitis; J&J adds pace to RSV vaccine race; Sarepta leapfrogs Pfizer in DMD gene therapy; and how real-world evidence and randomized trials might go together.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 8 October 2021, including: will a new oral antiviral be transformative for COVID?; OX40 drugs gain prominence in atopic dermatitis; Johnson & Johnson adds pace to RSV vaccine race; Sarepta Therapeutics, Inc. leapfrogs Pfizer Inc. in DMD gene therapy; and how real-world evidence and randomized trials might go together.

This and all our other podcasts are available on the Informa Pharma Intelligence channel on Apple PodcastsGoogle PodcastsSoundCloudTuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.  

Stories mentioned in this episode:

 

(Also see "J&J Sets The Pace In Race To $10bn RSV Vaccine Market" - Scrip, 4 Oct, 2021.)

(Also see "Sarepta Leapfrogs Pfizer In The US, Launching DMD Gene Therapy Pivotal Trial" - Scrip, 4 Oct, 2021.)

(Also see "Janssen’s Sarich: Randomized Controlled Trials, Real-World Evidence Go Best Together" - Scrip, 4 Oct, 2021.)

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC145209

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel